European Approval Granted for Cotavance Drug-Eluting Balloon

 

May 18, 2011

May 17, 2011 - Medrad Inc., a business of Bayer HealthCare, today announced it has received CE Mark for its Cotavance Paclitaxel Coated Balloon Angioplasty Catheter with Paccocathtechnology. The Cotavance catheter is used in percutaneous interventions for the treatment of peripheral arterial disease (PAD) and is approved for balloon dilation of stenotic lesions in the iliac and infrainguinal arteries while applying paclitaxel to the vessel wall to inhibit restenosis. Medrad Interventional has started selling its Cotavance catheter in countries where it has already received regulatory approval, including select European and Middle East countries. The announcement was made in conjunction with the Congress of the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) in Paris.

"Effective treatments for peripheral artery disease continue to be a major medical challenge," said Professor Gunnar Tepe, M.D, of Klinikum Rosenheim in Rosenheim, Germany. "The recent European approval of the Cotavance catheter offers an innovative new approach for improving patient outcomes. Importantly, the only positive long-term clinical results to date with drug-eluting balloons have used the Paccocath technology to successfully keep coronary and peripheral vessels open wider over time compared to standard therapies."

The Paccocath technology is a proprietary drug matrix applied to the balloon of an angioplasty catheter. The matrix consists of paclitaxel, long used in drug-eluting stents to treat cardiovascular disease, and a radiologic contrast agent, Ultravist 370. When the balloon is inflated to dilate the narrowed vessel, paclitaxel is delivered directly to the diseased area. Bayer Schering Pharma AG is the owner of the Paccocath technology and Medrad Interventional is developing and marketing it under the brand name Cotavance.

Medrad’s commitment to further advancing the treatment of PAD is demonstrated by the initiation of randomized clinical studies examining the safety and performance of the Cotavance product for treating diseased arteries above and below the knee. Two of these studies, EURO CANAL and DEFINITIVE AR (sponsored by ev3 Inc., a Covidien company, using Cotavance catheters), are expected to begin enrolling patients this summer. Additionally, the COPA CABANA and RIVER studies will be initiated at a later date. Collectively, these studies will enroll more than 640 patients in approximately 90 sites around the world. Information from these studies is intended to expand the scientific evidence of the Cotavance catheter and Paccocath technology and should provide valuable data for the clinical community toward optimum care for patients suffering from PAD.

Medrad is pursuing CE Mark certification for the next-generation Cotavance product with innovations that include enhanced drug dose application, a new catheter platform and a full range of catheter sizes. This advanced technology is expected to be available in Europe in the second half of 2011. The company is also moving forward with the Investigational Device Exemption (IDE) process as one of the steps in gaining U.S. Food and Drug Administration (FDA) approval for Cotavance product.

For more information: http://www.Medrad.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.